Cognitive behavioral therapy, exercise training, and cognitive remediation for patients with post-COVID-19 condition: protocol of an open-label randomized controlled trial Authors: Clément Gouraud, Agathe Ancellin-Geay, Corentin Verot, Isabelle Bergeras, Laura Poudevigne, Lucile Cormier, Séverine Gilbert, Frédéric Limosin, Laurence Lacoste, Diane Ribayrol, Charles Ouazana Vedrines, Victor Pitron, Karima Mesbahi-Ihadjadene, Hendy Abdoul, Jessica Rousseau, Alexandra Kachaner, Brigitte Ranque, Patricia Thoreux, Cédric Lemogne Published: 2025 ABSTRACT AbstractBackgroundEffective rehabilitation programs targeting transdiagnostic mechanisms of persistent physical symptoms are needed in long COVID. We present a transparency-focused description of the protocol of an open-label randomized controlled trial designed to evaluate the efficacy and tolerance of a multidisciplinary intensive rehabilitation program versus usual care.MethodsAfter a day-hospital multidisciplinary evaluation program including minimal psychoeducation and personalized recommendations, patients presenting with persistent symptoms after COVID-19 are proposed to participate to the study. The intervention consists of a 6-week rehabilitation program with groups of 3 to 5 patients attending three day-hospital sessions per week. The rehabilitation program combines adapted physical activity (three sessions per week with progressive exertion thresholds), cognitive remediation (two computer-based personalized sessions per week) and cognitive behavioral therapy (CBT, two sessions per week: one group session and one individual session). CBT sessions encompass psychoeducation, cognitive restructuring, behavioral activation and gradual exposure, and problem-solving skills. Our primary outcome is health-related quality of life (HRQoL) at 6 months, measured with the Physical Component Score (PCS) of the 12-item Short-Form Health Survey. The secondary outcomes are the Mental Component Score (MCS) at 6 months, PCS and MCS at 3 months, the main persistent symptoms (fatigue, dyspnea, cognitive complaints, pain) and associated psychological burden at 3 and 6 months, and patients’ satisfaction at 3 months. All included patients undergo an inclusion visit including a physical condition evaluation, a neuropsychological assessment, a first consultation with the CBT therapist, and the completion of several questionnaires for the secondary outcomes (Pichot scale, Borg scale, Cognitive Difficulties Scale, pain numeric scale, and Somatic Symptom disorder-B criteria scale). These evaluations are repeated at 3- and 6-month follow-up. All analyses will be performed in intention to treat following CONSORT Statement recommendations.DiscussionOur goal is to demonstrate that a multidisciplinary intensive rehabilitation program combining adapted physical activity, cognitive remediation, and CBT leads to an improvement in HRQoL in the long term (i.e., six months after a multidisciplinary evaluation program including minimal psychoeducation and personalized recommendations) in patients with long COVID, while being feasible, acceptable, and safe.Trial registrationNCT number NCT05532904, registration date: 2022–09-07.Supplementary InformationThe online version contains supplementary material available at 10.1186/s40359-025-03820-8.Keywords: Long COVID, Clinical trial, CBT, Adapted physical activity, Cognitive remediation, Multidisciplinary care Introduction Post-COVID-19 persistent symptoms may affect quality of life months, or even years after an infection with SARS-CoV-2. This situation, labeled as ‘long COVID’ or ‘post-COVID-19 Condition’ according to the World Health Organization (WHO), is frequent and constitutes a public health challenge, even if its prevalence varies widely depending on the definition used [1]. Despite considerable research efforts worldwide, the pathophysiology of long COVID remains poorly understood and no specific treatment has been validated to date [2]. Considerable emphasis has been placed on identifying effective rehabilitation programs targeting transdiagnostic mechanisms of persistent physical symptoms [3]. For instance, adapted physical activity has proven effective in similar conditions such as chronic fatigue syndrome [4] and encouraging results have been found in post-COVID-19 condition [5, 6]. Likewise, cognitive behavioral therapy (CBT) has been shown to be effective for persistent physical symptoms [7–10] and promising results were obtained in the context of long COVID [11–14]. Since cognitive complaints, frequently referred to as “brain fog”, are among the most frequent symptoms of long COVID, with objective measures suggesting impairment of attention, working memory, and executive functions [15, 16], cognitive remediation has also been recommended [17–21], although negative results have been reported [22]. According to a biopsychosocial perspective [23, 24], comprehensive and multidisciplinary care is needed. From a transdiagnostic perspective, various interventions are potentially effective on persistent symptoms [3], such as providing a biopsychosocial explanatory model for persistent symptoms in general [3], adapted physical activity [4], and CBT [7–10], for chronic fatigue, as already mentioned. A recent living systematic review also highlights that CBT and adapted physical activity are effective for reducing fatigue and improving physical functioning in long COVID [25]. Therefore, we have developed a multidisciplinary outpatient intensive rehabilitation program combining adapted physical activity, CBT, and cognitive remediation for patients with long COVID. Here, we present a transparency-oriented protocol describing the study methods, including the planned statistical analyses and a priori hypotheses, prior to obtaining the actual results. After attending a multidisciplinary consultation devoted to the evaluation of persistent post-COVID-19 symptoms, including minimal psychoeducation and personalized recommendations, patients meeting the inclusion criteria are invited to participate in an open-label randomized controlled trial designed to evaluate the efficacy and tolerance of this rehabilitation program. Patients are randomized between the treatment group and the usual care control group. Our primary objective is to evaluate health-related quality of life (HRQoL) at 6 months in patients with post-COVID-19 condition who attended a 6-week personalized multidisciplinary outpatient rehabilitation program consisting in three day-hospital sessions per week. The secondary objectives are to evaluate HRQoL at 3 months, the main persistent symptoms (fatigue, dyspnea, cognitive complaints, pain) and associated psychological burden at 3 and 6 months, and patients' satisfaction at 3 months. Methods Study design and participants The ECHAP-COVID trial (Evaluation et Comparaison d’une prise en charge multi-disciplinaire Hospitalière versus liste d’Attente en cas de symptoms Persistants après un episode aigu de COVID-19) is a prospective unicentric open-label randomized controlled trial that received ethical approval from CPP Est III by the Assistance Publique-Hôpitaux de Paris on 04/05/2022. Figure 1 presents the overall study protocol (Fig.1). Overall study protocole Eligible participants are recruited, after giving written informed consent, from the CASPer-COVID program (Circuit Ambulatoire de prise en charge des Symptômes Persistants après un épisode de COVID-19) in a large tertiary care university hospital in Paris. This program, which has been described in details elsewhere [26], is referenced by the health regional agency of the Paris area for managing post-COVID-19 condition. It is a multidisciplinary day-hospital evaluation program dedicated to patients with post-COVID-19 condition. After referral by their general practitioner, patients are invited to complete a questionnaire on their medical situation. First, the medical coordinator of the program (BR) checks that patients underwent adequate medical work-up, depending of their symptoms. Thereafter, patients undergo a multidisciplinary day-hospital evaluation with three consecutive one-hour consultations: 1) with an internist or infectious disease specialist to explore alternative diagnoses; 2) with a psychiatrist to assess psychiatric comorbidities and cognitive and behavioral mechanisms potentially involved in symptom maintenance (i.e., classical conditioning, focused attention on bodily functioning, catastrophizing, avoidance of symptoms and intolerance to uncertainty); and 3) with an adapted physical activity specialist to evaluate physical abilities and exercise habits. Then, patients receive personalized recommendations, including additional medical investigations, adapted physical activity programs, and appropriate psychological care when necessary. Furthermore, when cognitive and behavioral mechanisms that may contribute to symptom persistence are identified during the psychiatric consultation, a brief psychoeducational intervention is provided, along with tailored therapeutic recommendations targeting these mechanisms (e.g., progressively reducing symptom avoidance). Following this multidisciplinary evaluation, patients are offered a clinical follow-up telephone assessment at three months to explore the global evolution of symptoms [27]. Inclusion criteria are: Having had an initial episode of symptomatic COVID-19 according to one of the following criteria: SARS-CoV-2 PCR positive test, SARS-CoV-2 antigenic positive test, SARS-CoV-2 serology positive test, prolonged anosmia/agueusia of sudden onset, or typical chest CT scan Having had an initial episode of symptomatic COVID-19 according to one of the following criteria: SARS-CoV-2 PCR positive test, SARS-CoV-2 antigenic positive test, SARS-CoV-2 serology positive test, prolonged anosmia/agueusia of sudden onset, or typical chest CT scan Still having at least one of the initial symptoms and possibly new symptoms including fatigue, dyspnea, cognitive impairment or pain beyond 4 weeks after the onset of the acute phase of the disease Still having at least one of the initial symptoms and possibly new symptoms including fatigue, dyspnea, cognitive impairment or pain beyond 4 weeks after the onset of the acute phase of the disease These initial and persistent symptoms are not better explained by another diagnosis unrelated to COVID-19 These initial and persistent symptoms are not better explained by another diagnosis unrelated to COVID-19 These symptoms are the cause of an alteration in quality of life and global functioning deemed significant by the patient These symptoms are the cause of an alteration in quality of life and global functioning deemed significant by the patient Having an indication to either adapted physical activity, CBT, or cognitive remediation Having an indication to either adapted physical activity, CBT, or cognitive remediation Exclusion Criteria are: Medical emergency requiring management not compatible with research Medical emergency requiring management not compatible with research Neuropsychiatric disorder likely to alter cognitive functions, prior to COVID-19 Neuropsychiatric disorder likely to alter cognitive functions, prior to COVID-19 Medical contraindication to adapted physical activity such as pericarditis or progressive myocarditis Medical contraindication to adapted physical activity such as pericarditis or progressive myocarditis Patient under state medical assistance Patient under state medical assistance Patient who does not speak French Patient who does not speak French Pregnancy Pregnancy Patients are not eligible if they already benefit from similar care programs (including adapted physical activity, cognitive remediation, and CBT). Besides that, patients included in the ECHAP-COVID trial can benefit from usual care, including those recommended after the CASPer-COVID program and the clinical follow-up telephone assessment at three months. After giving written informed consent, patients undergo computer-based randomization, during the consultation with the psychiatrist at the end of the CASPer-COVID program, or during another specific consultation. The data management team have generated a centralized computer-generated randomization list without stratification factors (not accessible to the investigator) using blocks of predefined size. Patients are assigned according to a 1:1 ratio. The allocation sequence is computer-generated through the electronic case report form (eCRF), and investigators are blinded to this sequence. After randomization, participants are immediately informed by the investigator of their group assignment. Outcomes Our main outcome is physical HRQoL 6 months after inclusion in the program in patients assigned to 6 weeks of personalized multidisciplinary outpatient management (intervention group) versus usual care (control group). HRQoL is evaluated with the 12-item Short-Form Health Survey (SF-12). The SF-12 is a shortened version of the 36-Item Short-Form Health Survey with 12 questions exploring HRQoL through physical and mental health domains, leading to two summary scores (a Physical Component Score, PCS-12, and a Mental Component Score, MCS-12), with higher scores indicating higher levels of quality of life [28]. The SF-12 has demonstrated good reliability, with Cronbach’s α coefficients typically ranging from 0.70 to 0.89 across international studies [28, 29], including in populations with physical persistent symptoms such as chronic pain [30]. The French version is based on the translation and cultural adaptation of the SF-36 performed by Leplège et al. [31], and it has also shown satisfactory internal consistency (Cronbach’s α > 0.85). Patients complete the SF-12 at baseline, three months, and six months. Therefore, to define a single primary outcome, we consider PCS-12 at 6 months as our primary outcome. Secondary outcomes are MCS-12 at 6 months, PCS-12 and MCS-12 at 3 months, main persistent symptoms (fatigue, dyspnea, cognitive complaints, pain) and associated psychological burden at 3 and 6 months, and patients’ satisfaction at 3 months. All outcomes, primary and secondary, were patient-reported outcome measures (PROMs) as pre-specified in the original protocol (https://clinicaltrials.gov/study/NCT05532904; registration date 2022–09-07). For all data, a Clinical Research Associate performs data entry. Anonymized data is entered in a eCRF and stored on a secure server. The database is frozen until the start of the analyses. Assessment at baseline After inclusion in the study, all patients receive a complementary multidisciplinary assessment to complete the evaluation previously conducted as part of the multidisciplinary day-hospital evaluation program. This assessment consists of a physical condition evaluation, including a stress test and a consultation with a sports medicine physician, as well as a neuropsychological assessment by a psychologist specialized in neuropsychology, and a first consultation with the psychologist responsible for CBT, including further psychoeducation and recommendations regarding potentially modifiable maintenance mechanisms (e.g., progressively reducing symptom avoidance). Collected variables at inclusion include: Clinical variables: general parameters (weight, height, heart rate, blood pressure, respiratory rate), personal medical and psychiatric history, vaccination status, and current persistent symptoms. Clinical variables: general parameters (weight, height, heart rate, blood pressure, respiratory rate), personal medical and psychiatric history, vaccination status, and current persistent symptoms. Characteristics of the acute infection: date of infection, date of symptom onset and type of symptoms, severity of the episode (need for hospitalization, oxygen therapy, or intensive care), additional tests performed. Characteristics of the acute infection: date of infection, date of symptom onset and type of symptoms, severity of the episode (need for hospitalization, oxygen therapy, or intensive care), additional tests performed. Systematic completion of several questionnaires for the main and secondary outcomes: HRQoL (SF-12 scale) [28], fatigue (Pichot scale) [32], dyspnea (Borg scale) [33, 34], cognitive complaints (Cognitive Difficulties Scale, CDS) [35], pain (numerical scale from 0 to 10), and psychological burden associated with persistent symptoms (Somatic Symptom Disorder-B criteria scale, SSD-12) [36, 37]. Systematic completion of several questionnaires for the main and secondary outcomes: HRQoL (SF-12 scale) [28], fatigue (Pichot scale) [32], dyspnea (Borg scale) [33, 34], cognitive complaints (Cognitive Difficulties Scale, CDS) [35], pain (numerical scale from 0 to 10), and psychological burden associated with persistent symptoms (Somatic Symptom Disorder-B criteria scale, SSD-12) [36, 37]. Physical condition and exercise habits variables through various tests (Sit to Stand test, Ito Shirado test, Sit and Reach test, 6-minute walk test). Physical condition and exercise habits variables through various tests (Sit to Stand test, Ito Shirado test, Sit and Reach test, 6-minute walk test). Data from the stress test performance (maximum heart rate, VO2 max (i.e. maximal oxygen volume uptake), maximum power). Data from the stress test performance (maximum heart rate, VO2 max (i.e. maximal oxygen volume uptake), maximum power). Comprehensive neuropsychological assessment including: the Montreal Cognitive Assessment (MoCA, French version) [38], the 16-item Free and Cued Recall [39], the Trail Making Test A and B [40], the WAIS III digit span and coding subtests [41], categorical and lexical fluency tests [42], the d2-R Test of Attention [43], and the Functional Impact Assessment Scale (ERF) [44]. Comprehensive neuropsychological assessment including: the Montreal Cognitive Assessment (MoCA, French version) [38], the 16-item Free and Cued Recall [39], the Trail Making Test A and B [40], the WAIS III digit span and coding subtests [41], categorical and lexical fluency tests [42], the d2-R Test of Attention [43], and the Functional Impact Assessment Scale (ERF) [44]. Inclusions are actually ongoing at the time of submission. The first patient has been included in the study on January 18th 2023. General overview of the intervention The intervention includes: 1) physical activity adapted to the results of the VO2max exercise test (three sessions per week); 2) CBT (two sessions per week: one group session and one individual session); and 3) computer-based cognitive remediation (two group sessions per week). Compared to the original protocol (https://clinicaltrials.gov/study/NCT05532904; registration date 2022–09-07) the following improvements were added on March 2023. Originally, only patients with a SSD-12 score ≥ 26 would be offered CBT. However, in this context, a vast majority of patients presents with at least some cognitive or behavioral features that could be addressed with CBT [26], while some of these mechanisms may not be adequately captured by the SSD-12 score [37]. Therefore, all participants are offered CBT. Likewise, since cognitive remediation is personalized according to a comprehensive neuropsychological assessment, all participants are offered cognitive remediation rather than only those with cognitive complaints and/or neuropsychological impairment. In addition, based on the feedback from patients included in the first group (n = 5), who reported poor tolerance of adapted physical activity sessions, even at the first exertion thresholds, and poor adherence to the hypothesis of cognitive and behavioral factors contributing to symptom persistence, the following changes were made for patients included in the subsequent groups: no effort was required at the first exertion threshold in order to avoid intolerance and avoidance of physical activity. Individual CBT sessions have been intermixed with group CBT sessions, with an early explanation of the hypothesis of cognitive and behavioral perpetuating factors (first CBT group session) and of the ‘micro-choices’ paradigm (first individual CBT session) to provide patients with alternative explanations of symptoms triggered by exercise and to foster adherence to exposure components of CBT. These early modifications were introduced after the first group of five patients completed the six-week protocol and therefore took place before any of the 3- or 6-month follow-up visits, that is before the assessment and collection of the primary and secondary outcomes. Furthermore, we planned to assess and collect data regarding the number of attended and missed sessions in order to explore adherence to the program for patients randomized in the intervention group and to perform sensitivity analyses excluding patients who did not receive the full intervention program. Adapted physical activity Details of the 18 sessions of adapted physical activity are displayed in Supplemental Table S1. The goal is to improve the functional abilities of patients both physically and mentally. Adapted physical activity specialists, trained and experienced in rehabilitation programs through adapted physical activity lead the sessions. The difficulty of the sessions are adapted to the validated fitness tests measuring cardio-respiratory and functional abilities (see above) and to patients’ feedback. The first part of each session (45 min) takes place in a group performing physical exercise by means of accessible and playful activities (Supplemental Table S1). The second part (30 min) consists of ergocycle training. Ergocycle sessions are performed according to the results of the initial stress test and are adaptable according to the Borg scale (for exertional dyspnea) and heart rate, after a first experience with no effort as a first introduction session. Cognitive behavioral therapy A total of 12 sessions are proposed, half as group sessions and half as individual sessions (Supplemental Table S2). The sessions are conducted by clinical psychologists trained in CBT (AA and DR). The content of the sessions is adapted from CBT protocols for patients experiencing persistent physical symptoms. It includes the following components: psychoeducation (providing information about the mind–body connection, emphasizing how psychological factors can influence physical symptoms and their persistence); cognitive restructuring (identifying and challenging maladaptive thoughts related to symptoms, replacing negative or catastrophic thoughts with more balanced and realistic ones); behavioral activation and gradual exposure (gradually encouraging patients to engage in activities they may avoid due to symptoms); stress management (teaching relaxation techniques, coping strategies, and stress reduction methods); problem-solving skills (enhancing patients' ability to address practical problems related to their symptoms); mindfulness and acceptance (fostering awareness of the present moment and accepting physical sensations without judgment). To maximize access to CBT exercises for patients who experience cognitive impairments, leaflets are given at the end of each session. These leaflets summarize aspects of psychoeducation and good practices, offer space to report results from the CBT exercises, or remind participants about instructions related to these exercises. Participants are invited to express and accept their doubts and ambivalence about the cognitive and behavioral model presented as one of multiple ways to address the “all or nothing” dynamic. The group and individual sessions are intermixed to optimize the integration of top-down and bottom-up components. In addition to general principles, some specific features are used in the CBT program. The exposure component of the CBT intervention notably relies on the ‘micro-choices’ paradigm developed by Kvale et al [45] with a transdiagnostic perspective, that was subsequently found to be effective in post-COVID-19 fatigue [13]. This approach is described as a “shift in focus, from targeting and monitoring symptoms, to focus on micro-choices in order to facilitate increased levels of physical activity and functioning”. Participants are asked to constitute a pool of activities that meet three criteria: 1) valued by participants as meaningful and/or pleasurable; 2) avoided or degraded due to symptoms; and 3) constituting small changes, perceived by participants as attainable accounting for their current symptoms. The first individual sessions are dedicated to setting and reevaluating goals. As cognitive biases, such as catastrophizing, tend to reframe symptom perception and affect motivation for exposure therapy, another part of the CBT program is dedicated to cognitive restructuring. Specifically, participants are asked to report one “stone” and as many “pearls” as they wish, with a minimum of one. Stones are defined as a frustrating event related to symptoms, while pearls are achievements and more widely meaningful moments lived despite the symptoms. Participants are told that one of the goals of the exercise is to bring attention to small events that could have otherwise stayed unnoticed, and to take pride and pleasure in progress and attempting activities again. The CBT program also addresses the focused attention on bodily functioning through mindfulness, and more precisely a body scan exercise. Participants are informed that the main goal is not to feel relaxed or happier, but to redraw attention to different and sometimes new sensations. On a theoretical ground, mindfulness-based exercises aim at: 1) helping the patients to grasp the interplay of attention with bodily perceptions; 2) providing them with an alternative behavior to cognitive avoidance of the symptoms; 3) increasing their awareness regarding mind wandering and automatic thoughts. The same session also involves an exercise of cardiac coherence exercise, introduced as a way to help cope with anxiety bursts. Participants are encouraged to try those exercises during sessions and anytime they feel the need. Cognitive remediation A program of 12 group sessions is offered to participants, with 2 sessions per week for 6 weeks (Supplemental Table S3). All sessions are supervised by a psychologist specialized in neuropsychology (LP, IB and LL) and specifically trained in computer-assisted cognitive remediation, and are conducted in person, using individual computer workstations. The cognitive remediation program is based on the NEAR program, which combines computerized cognitive stimulation and bridging group sessions [46]. The cognitive stimulation part is conducted with the PRESCO software, which trains overall cognitive functions through a large variety of exercises to generate a personalized program for each participant. This personalized program is developed based on two indicators: the results of the neuropsychological assessment (using the conventional threshold of one standard deviation below the mean, as typically applied in cognitive testing) and individualized objectives. For participants who do not present clear cognitive impairments according to this criterion, the program is instead tailored according to the individual’s subjective complaints. As described in the literature, we primarily expect to observe deficits in attention, working memory, or executive functions. However, we also intend to tailor the proposed intervention based on the same criteria. The aim of the first session is to provide participants with general information about their cognitive functioning, so that they could adopt a shared language that would be useful for further sessions. The program and the concept of cognitive remediation are also described. In the second session, each participant's subjective cognitive complaints are specified, and two personalized objectives are defined, focusing on difficulties observed in daily life. The individualized objectives are defined for each participant, focusing on difficulties observed in daily life. Individualized objectives are defined in collaboration with the neuropsychologists, with the aim of identifying objectives that would be realistic and measurable. These initial stages of remediation, dedicated to goal setting, are particularly important to foster engagement and enhance intrinsic motivation. Finally, the software is presented to the participants and a group exercise is carried out to discover the interface, instructions, levels, and procedure. The following sessions are modelled in two parts: Cognitive stimulation with computerizes exercises At each session, participants are asked to complete three exercises lasting 15 minutes per exercise, focusing on specific cognitive domains. Participants work independently, each on an individual session guided by a tracking sheet with personalized exercises. The neuropsychologist interacts with each participant individually, aiming to help them develop strategies and to provide feedback on their performance. Participants are invited to record these strategies on their personalized exercise sheets. Cognitive stimulation with computerizes exercises At each session, participants are asked to complete three exercises lasting 15 minutes per exercise, focusing on specific cognitive domains. Participants work independently, each on an individual session guided by a tracking sheet with personalized exercises. The neuropsychologist interacts with each participant individually, aiming to help them develop strategies and to provide feedback on their performance. Participants are invited to record these strategies on their personalized exercise sheets. Bridging groups The aim is to transfer the benefits of cognitive stimulation into everyday life, by establishing links between the cognitive functions trained and their involvement in various everyday situations. Bridging groups consist in discussions between participants and are moderated by the neuropsychologist to share the different strategies used during the exercises and find examples of applications in daily life. Several themes are discussed: strategies for improving attention, memory, organization, factors affecting cognitive functioning, and consolidation of acquired skills. Bridging groups The aim is to transfer the benefits of cognitive stimulation into everyday life, by establishing links between the cognitive functions trained and their involvement in various everyday situations. Bridging groups consist in discussions between participants and are moderated by the neuropsychologist to share the different strategies used during the exercises and find examples of applications in daily life. Several themes are discussed: strategies for improving attention, memory, organization, factors affecting cognitive functioning, and consolidation of acquired skills. The final session is an evaluation of the cognitive remediation program with the participants. During this session, various ways of transferring the benefits of the program into everyday life are discussed. The cognitive remediation program aims to go beyond simple cognitive training, through facilitating awareness and the development of varied and effective strategies, and by reinforcing the participants' sense of self-efficacy. Control group Participants randomized into the control group receive both usual care, as any other patient attending the multidisciplinary day-hospital CASPer-COVID evaluation program, and a first CBT consultation during the complementary baseline assessment. During the CASPer-COVID program, all patients receive medical conclusions, minimal psychoeducation regarding cognitive and behavioral mechanisms potentially involved in symptom maintenance (i.e., classical conditioning, focused attention on bodily functioning, catastrophizing, avoidance of symptoms and intolerance to uncertainty), and recommendations for self-guided rehabilitation. Specifically, they are provided with advices regarding how to mitigate maintenance mechanisms (e.g., progressively reducing symptom avoidance) and with exercise sheets and a tailored physical activity program. Depending on the initial assessment and geographical availability, a referral to a health and sports facility or the establishment of psychiatric care or psychological support may also be recommended. All patients attending the CASPer-COVID program are also offered a clinical follow-up telephone assessment at three months to explore the global evolution of symptoms [27]. In addition, during the complementary baseline assessment, a first CBT consultation is provided for all patients, including further psychoeducation and recommendations regarding modifiable maintenance mechanisms. Follow-up visits Two follow-up visits are proposed to participants, at 3 months (± 2 weeks) and 6 months (± 2 weeks) after the beginning of the intervention. An evaluation is performed during these follow-up visits: Physical and mental HRQoL (SF-12 scale), fatigue (Pichot scale), dyspnea (Borg scale), cognitive complaints (CDS), pain (numerical scale), and psychological burden associated with persistent symptoms (SSD-12). Patients are proposed a physical condition evaluation, including physical abilities tests (Sit to Stand test, Ito Shirado test, Sit and Reach test, 6-min walk test) a stress test and a consultation with a sports medicine physician. Patients are also proposed a control of the neuropsychological assessment with a psychologist specialized in neuropsychology (see details of this assessment above). To promote participant retention and complete follow-up, the Clinical Research Associate is responsible for regularly attempting to call participants by phone to ensure that follow-up visits are completed and that the primary outcome measure is collected. In case of important difficulties to reach some participants, one of the investigators could participate to ensure the primary outcome measure is collected. Safety The investigator can temporarily or permanently discontinue a patient’s participation in the research for any reason that impacts his or her safety or would best serve the patient's interests. Participants can also stop their participation at any time, after informing the investigator. An observation log lists the various reasons for discontinuation of participation. Potential adverse events (serious or not) are reported within the framework of vigilance established in the context of care. Statistical analyses The analyses will begin after the completion of the follow-up visits and no intermediary analysis will be allowed. All analyses will be performed in intention to treat following CONSORT Statement recommendations. A descriptive flowchart of patients’ screening and inclusion will be realized. All statistical tests will be bilateral with alpha risk < 0.05. All analyses will be produced with SAS software 9.4 and or R software 4.0.3. We designed our study to be able to identify a difference of 4 points between PCS-12 of each group. This threshold is above the “Minimum Clinically Important Difference” of 2 for PCS for the general use of the SF-12 [47] and reflects our intention to employ a more conservative approach in the context of a clinical trial aimed at achieving a meaningful clinical improvement [48]. To detect a 4-point difference in PCS-12 between groups, assuming a standard deviation of 5 points, a two-sided α risk of 0.05 and 90% power, the required sample size was estimated at 33 participants per arm. Allowing for a 15% attrition rate, this number was increased to 40 participants per arm to maintain the desired statistical power. As a sensitivity analysis, due to early modifications to the program based on the patients’ feedback from the first group, we plan to analyze the data again excluding the first group of the intervention arm. Other sensitivity analyses will exclude participants who missed more than three intervention sessions out of 18, as a proxy measure of patient adherence to the proposed care plan. A descriptive analysis will be performed to describe patients’ characteristics at screening and inclusion. Quantitative variables will be described with means and standard deviations or medians and interquartile ranges according to data distribution. Qualitative variables will be described with numbers and percentage. While randomization should allow comparability between groups, descriptive analyses could identify potential confounding factors and allow adjustment of the analyses for these potential confounding factors in sensitivity analyses. The primary outcome, PCS-12, will be described in each arm with mean, standard deviation, median, quartiles and number of missing data. Comparisons between PCS-12 at 6 months will be assessed with a Student’s t-test or a non-parametric test according to data distribution. Differences between 6-month and baseline scores will be estimated in each group and compared with Student t-test or non-parametric test according to data distribution. Potential missing data at 6-month for the primary outcome (PCS-12) will be addressed by multiple imputation. Mixed regression models will be implemented to explore SF-12 scores variations accounting for repeated measures, the actual timing of the follow-up visits, and any potential confounding factor. Secondary outcomes will be compared with Student’s t-test or Wilcoxon test for quantitative variables. To handle the risk of alpha error inflation due to multiple comparisons, we will implement the False Discovery Rate (FDR) correction method. Mixed regression models will be implemented to explore secondary outcomes in the same way as the primary outcome. All analysis will be described in a statistical analysis plan before data completion and database frozen. Data management and analysis will be handled by a specific team, independent from investigators. Only the statistician team will have access to the final dataset. The statistician team will conduct the analyses while being blinded to group allocation. In case the final dataset is required by the investigators or other investigators disclosure of contractual agreements will be implemented. Trial results are planned to be communicated by scientific publication. Discussion The present open-label randomized controlled trial is designed to explore the efficacy of a multidisciplinary intensive rehabilitation program for patients with persistent symptoms after COVID-19. We propose a transparency-oriented protocol description to present the analytical plan, including primary outcome and a priori hypotheses, prior to obtaining the results. Our goal is to demonstrate that this rehabilitation program leads to an improvement in physical HRQoL in the long term (i.e., six months after a multidisciplinary evaluation including minimal psychoeducation and personalized recommendations), while being feasible, acceptable, and safe. The secondary objectives are to explore mental HRQoL, to investigate whether the patients experience an improvement of the main symptoms and associated psychological burden, and are satisfied with the intervention, while also exploring physical HRQoL in the short term. Various studies have already explored rehabilitation programs for patients with long COVID. Encouraging results have been published regarding interventions based on adapted physical activity programs, CBT, or cognitive remediation [25]. A recent living systematic review suggests that adapted physical activity, CBT, and a combination of physical and mental health rehabilitation might be effective in improving long COVID symptoms [25]. A recent meta-analysis on physical exercise-based rehabilitation showed beneficial effects not only on main physical symptoms (dyspnea and fatigue) and depression, but also on physical performance (6-min walk test and expiratory volume) and on quality of life [5]. Despite these encouraging results, the potential benefits of adapted physical activity are still debated, based on limited effect sizes and the putative risk of symptom exacerbation, frequently referred to as “post-exertional symptom exacerbation” or “post-exertional malaise”. However, although post-exertional symptom exacerbation is frequently reported by patients with long COVID, its temporal relationship with objectively measured physical activity has been challenged [49] and the association with poor long-term outcomes have not been substantiated in randomized controlled trials [50]. Meanwhile, numerous randomized trials continue to show results in favor of adapted physical activity [51, 52]. Huth and colleagues proposed a CBT program that showed great feasibility and results suggesting significantly reduced fatigue and improved coping with symptoms [12]. The effectiveness of CBT programs on fatigue in long COVID was also supported by a study in the Netherlands that showed that the observed effect persisted for 6 months after the intervention [11]. Another study found that a 3-day micro-choice-based rehabilitation program was associated with reduced fatigue and increased functional levels 3 months after the intervention [53]. The micro-choice approach proposes a “shift in focus from targeting symptoms to targeting insignificant micro-choices that facilitate increased flexibility and level of functioning” and was associated with rapid improvements in fatigue and functional levels in patients with long COVID. These results show that CBT is a very well-accepted type of care in this context. This observation is particularly important for patients with long COVID who regularly experience stigmatization during their care pathway [54, 55]. Moreover, we have already demonstrated that the proposition of a pathophysiological model of persistent symptoms involving the participation of cognitive and behavioral mechanisms within the framework of a multidisciplinary day-hospital evaluation program was very well accepted [26]. Furthermore, combining this minimal psychoeducation with personalized recommendations for self-guided rehabilitation was associated with substantial symptom improvement of the patients at 3-month follow-up [27]. As regards cognitive remediation, several studies report results suggesting great acceptability and even potential efficacy on cognitive symptoms, although negative findings have also been reported [22]. Duñabeitia et al. reported a before-and–after study of a home-based digital therapeutic program suggesting that cognitive remediation was relevant and sustainable and associated with increased cognitive performance in most participants [21]. Other studies explored the efficacy of different cognitive remediation settings, through a mobile application [18], with a rehabilitation program mainly focused on psychoeducation with group sessions [20] or through a multidisciplinary rehabilitation program associating cognitive remediation and physiotherapy rehabilitation [19]. These studies exhibited promising results, showing improvements in subjective cognitive complaint [20] but also significant improvements in cognitive performances [18, 19] or even an improvement in physical function [18]. Interestingly, one study found that the improvement in cognitive performances (measured by the MOCA score) was predicted by an increase in self-efficacy [18]. This latter observation is in line with some of the theoretical basis of the proposed cognitive remediation program, even if we unfortunately did not plan to measure self-efficacy. Of note, this study also found that an increase in health literacy was associated with a subsequent reduction of the number of persistent symptoms. These latter observations argue for the utilization of a multidisciplinary care program encompassing both cognitive and physical dimensions. As for our protocol, the rationale of proposing two sessions of cognitive remediation per week along with other sessions (i.e., adapted physical activity and CBT) through a multidisciplinary program should enhance acceptability and feasibility. Nevertheless, patients with more severe impairments may require more intensive care, and future studies should investigate the efficacy, while monitoring the acceptability, of more intensive intervention programs. The originality of the present program lies in that it offers a multidisciplinary approach that integrates adapted physical activity, CBT, and cognitive remediation. Furthermore, we do not only aim at reducing symptoms but also to explore the impact on overall functioning and well-being through a measure of HR-QoL. Although this trial is ongoing, we already gained some insights from the five first patients included who helped us to adapt the program and increase its acceptability. Regarding adapted physical activity, the original protocol involved an initial exposure to an effort intensity calculated from the results of the previously performed stress test, which corresponds to the proposed protocol for physical activity rehabilitation for other chronic conditions. However, given the massive functional limitations of some patients with long COVID and the feedback of patients included in the first group who reported poor tolerance of exercise training sessions, even for the first exertion thresholds, we decided to propose minimal or even no effort for the first exertion threshold, with a possibility given to the patients to change this for the next sessions. This observation is also consistent with the hypothesis of classical conditioning partially accounting for post-, per- or even pre-exertional symptom exacerbation [56], which emphasizes the importance of addressing cognitive biases that may hinder appropriate re-exposure [54]. We also observed poor adherence of the first group of patients to the hypothesis of cognitive and behavioral factors contributing to symptom persistence, contrasting with individual feedback from the multidisciplinary day-hospital CASPer-COVID evaluation program during which the patients were screened for eligibility and provided with minimal psychoeducation regarding these factors [26]. Based on patients’ feedback, we analyzed that further psychoeducation on cognitive and behavioral mechanisms in group session might have occurred too late in the original rehabilitation program, leaving purely physical interpretations of post-exertional symptom unchallenged. Therefore, in accordance with other CBT programs in long COVID [11, 12, 53], we then decided to introduce early the hypothesis of cognitive and behavioral perpetuating factors (i.e., during the first CBT group session) as well as the ‘micro-choices’ paradigm (during first the first CBT individual session) to provide patients with alternative explanations of symptoms triggered by exercise and foster adherence to exposure therapy components of CBT. Even though early modifications to the care program (i.e., changes to the exercise threshold and adjustments to CBT) may limit internal validity, these changes remain in line with the overall structure of the original protocol (number of sessions and overall content) and were implemented early on, starting with the second group, before any outcome criteria were assessed. However, the qualitative difference may undermine our ability to examine the efficacy of the intervention due to heterogenous practice between the first group (i.e. five patients) and the subsequent group. A further limitation of this care protocol lies in the impossibility of blinding patients, and therefore outcome assessors, as the outcomes consisted of PROMs. To conclude, this transparency-oriented protocol article presents the methods and a priori hypotheses of an open-label randomized controlled trial that aims to examine the efficacy of a multidisciplinary intensive rehabilitation program for patients with long COVID combining adapted physical activity, CBT and cognitive remediation. Previous programs based on one of these interventions showed good feasibility, acceptability and efficacy, but this multidisciplinary program is the first to integrate these three components in the hope of relieving patients in the long run. Supplementary Information Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Acknowledgements The authors thanks Gverd Kale for her insights regarding CBT for long COVID. Authors’ contributions PT, BR, and CL designed the study; CV and PT designed the adapted physical activity program; AAG, DR, CG and CL designed the cognitive behavioral therapy program; IB and LL designed the cognitive remediation program; CG, CL and HA designed the statistical analysis plan; CG, AA, CV, IB and CL drafted the article; all other authors revised it critically for important intellectual content. All authors have read and approved the final manuscript. Funding The present study is supported by a grant “AAP CoVID-1” from the “Assistance Publique - Hôpitaux de Paris” (AP-HP). During this process, the present study protocol underwent peer-reviewed process. AP-HP is the university hospital trust operating in Paris and its surroundings. It is the largest hospital system in Europe and one of the largest in the world. It receives an average of more than 10 million patients per year. AP-HP employs more than 90,000 people in 44 teaching hospitals linked with Paris Cité University (16 teaching hospitals), Sorbonne University (7 teaching hospitals), Paris Saclay University (6 teaching hospitals), the University of Créteil (5 teaching hospitals), and Sorbonne Paris North University (3 teaching hospitals). As a teaching hospitals network, AP-HP trust is in charge of training healthcare professionals and doctors and plays a prominent role in French healthcare research alongside Inserm. As a major player in French medical research, AP-HP regularly issues calls to proposals that undergo peer review and selection by a scientific committee. Funding sources had no role in the study design, data acquisition, statistical analysis, interpretation of the results, or writing the manuscript. Data availability No datasets were generated or analysed during the current study. Declarations Ethics approval and consent to participate The ECHAP-COVID program (Evaluation et Comparaison d’une prise en charge multi-disciplinaire Hospitalière versus liste d’Attente en cas de symptoms Persistants après un episode aigu de COVID-19) is a prospective unicentric open-label randomized controlled trial that received ethical approval from CPP Est III by the Assistance Publique-Hôpitaux de Paris on 04/05/2022. The study was designed in accordance with the principles outlined in the Declaration of Helsinki and adhered to relevant French legislation governing research involving human participants. Written informed consent is obtained for every participant to the ECHAP-COVID program. Monitoring of consents during the study will be realized by a Clinical Research Assistant appointed by the sponsor. independent audit planned apart from the sponsor and investigators. Protocol amendments are submitted to regulatory authorities according to regulatory procedures and then sent to the centers by email. If the protocol is amended with substantial modification, the patient information form is updated. As this study is not considered as including high risk intervention nor with an invasive outcome, there is no data monitoring committee involved. Consent for publication Not applicable for this article. Written informed consent is obtained for every participant to the ECHAP-COVID program. Competing interests CL reported non-financial support from Nordic Pharma, outside the submitted work. No other disclosures were reported. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Clément Gouraud, Email: clement.gouraud@aphp.fr. Cédric Lemogne, Email: cedric.lemogne@aphp.fr. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Supplementary Material 3. Data Availability Statement No datasets were generated or analysed during the current study.